$APDN 90 DAYS STOCK PRICE FORECAST
Stock Price
About the Company
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Similar Companies
| Name | Ticker | Market Capitalization (USD M) | Revenue (USD M) | Price/Book | Price/Earning | Net Margin (%) |
|---|---|---|---|---|---|---|
| Methanex Corp. | MEOH | 3786 | 4575 | 1.79 | 7.62 | 10.85 |
| Applied Dna Sciences Inc | APDN | 10 | 12 | 1.37 | -0.77 | -122.64 |
Applied DNA Sciences (APDN) to Release Earnings on Thursday
Applied DNA Sciences Company Profile (Get Rating) Applied DNA Sciences, Inc develops and markets DNA-based technology ...
Applied DNA Sciences (NASDAQ:APDN) PT Lowered to $4.00
Analysts anticipate that Applied DNA Sciences will post -1.32 EPS for the current year. Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its ...
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript
Q2 2022 Earnings Conference Call May 12, 2022, 04:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - ...
Applied DNA Sciences: Fiscal Q2 Earnings Snapshot
STONY BROOK, N.Y. (AP) _ Applied DNA Sciences Inc. (APDN) on Thursday reported a loss of $1.8 million in its fiscal second quarter. The Stony Brook, New York-based company said it had a loss of 23 ...
Applied DNA Sciences, Inc. (NASDAQ:APDN) Expected to Post Quarterly Sales of $4.65 Million
Wall Street analysts expect Applied DNA Sciences, Inc. (NASDAQ:APDN – Get Rating) to announce $4.65 million in sales for the current quarter, according to Zacks Investment Research. Two analysts ...
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA ...
Applied DNA Sciences Inc - Stock Quote APDN
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...
Applied DNA Sciences Inc.
1 Day APDN 11.35% DJIA 1.36% Russell 2K 3.11% Industrial Goods -0.35% ...
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
2022--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in cell-free, enzymatic DNA production, today announced consolidated financial results for the second ...
Applied DNA Sciences Inc - Stock Executive APDN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.